MARCOS ROBERTO DE MENEZES
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- State-of-the-art in radiomics of hepatocellular carcinoma: a review of basic principles, applications, and limitations(2020) SANTOS, Joao Manoel Miranda Magalhaes; OLIVEIRA, Brunna Clemente; ARAUJO-FILHO, Jose de Arimateia Batista; ASSUNCAO- JR., Antonildes N.; MACHADO, Felipe Augusto de M.; ROCHA, Camila Carlos Tavares; HORVAT, Joao Vicente; MENEZES, Marcos Roberto; HORVAT, NatallyRadiomics is a new field in medical imaging with the potential of changing medical practice. Radiomics is characterized by the extraction of several quantitative imaging features which are not visible to the naked eye from conventional imaging modalities, and its correlation with specific relevant clinical endpoints, such as pathology, therapeutic response, and survival. Several studies have evaluated the use of radiomics in patients with hepatocellular carcinoma (HCC) with encouraging results, particularly in the pretreatment prediction of tumor biological characteristics, risk of recurrence, and survival. In spite of this, there are limitations and challenges to be overcome before the implementation of radiomics into clinical routine. In this article, we will review the concepts of radiomics and their current potential applications in patients with HCC. It is important that the multidisciplinary team involved in the treatment of patients with HCC be aware of the basic principles, benefits, and limitations of radiomics in order to achieve a balanced interpretation of the results toward a personalized medicine.
- Lung radiofrequency ablation: post-procedure imaging patterns and late follow-up(2020) ARAUJO-FILHO, Jose de Arimateia Batista; MENEZES, Raonne Souza Almeida Alves; HORVAT, Natally; PANIZZA, Pedro Sergio Brito; BERNARDES, Joao Paulo Giacomini; DAMASCENO, Rodrigo Sanford; OLIVEIRA, Brunna Clemente; MENEZES, Marcos RobertoPurpose: To describe expected imaging features on chest computed tomography (CT) after percutaneous radiofrequency ablation (RFA) of lung tumors, and their frequency over time after the procedure. Methods: In this double-center retrospective study, we reviewed CT scans from patients who underwent RFA for primary or secondary lung tumors. Patients with partial ablation or tumor recurrence during the imaging followup were not included. The imaging features were assessed in pre-defined time points: immediate post-procedure, <= 4 weeks, 5 24 weeks, 25 52 weeks and >= 52 weeks. Late follow-up (3 and 5 years after procedure) was assessed clinically in 48 patients. Results: The study population consisted of 69 patients and 144 pulmonary tumors. Six out of 69 (9%) patients had primary lung nodules (stage I) and 63/69 (91 %) had metastatic pulmonary nodules. In a patient-level analysis, immediately after lung RFA, the most common CT features were ground glass opacities (66/69, 96 %), consolidation (56/69, 81 %), and hyperdensity within the nodule (47/69, 68 %). Less than 4 weeks, ground glass opacities (including reversed halo sign) was demonstrated in 20/22 (91 %) patients, while consolidation and pleural thickening were detected in 17/22 patients (77 %). Cavitation, pneumatocele, pneumothorax and pleural effusions were less common features. From 5 weeks onwards, the most common imaging features were parenchymal bands. Conclusions: Our study demonstrated the expected CT features after lung RFA, a safe and effective minimally invasive treatment for selected patients with primary and secondary lung tumors. Diagnostic and interventional radiologists should be familiar with the expected imaging features immediately after RFA and their change over time in order to avoid misinterpretation and inadequate treatments.
- BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA(2020) CHAGAS, Aline Lopes; MATTOS, Angelo Alves de; CARRILHO, Flair José; BITTENCOURT, Paulo Lisboa; VEZOZZO, Denise Cerqueira Paranaguá; HORVAT, Natally; ROCHA, Manoel de Souza; ALVES, Venâncio Avancini Ferreira; CORAL, Gabriela Perdomo; ALVARES-DA-SILVA, Mario Reis; BARROS, Fabio Marinho do Rego; MENEZES, Marcos Roberto; MONSIGNORE, Lucas Moretti; COELHO, Fabricio Ferreira; SILVA, Renato Ferreira da; SILVA, Rita de Cássia Martins Alves; BOIN, Ilka de Fatima Santana Ferreira; D`ALBUQUERQUE, Luiz Augusto Carneiro; GARCIA, José Huygens Parente; FELGA, Guilherme Eduardo Gonçalves; MOREIRA, Airton Mota; BRAGHIROLI, Maria Ignez Freitas Melro; HOFF, Paulo Marcelo Gehm; MELLO, Vivianne Barretto de; DOTTORI, Mariana Fonseca; BRANCO, Tiago Pugliese; SCHIAVON, Leonardo de Lucca; COSTA, Thaisa de Fátima AlmeidaABSTRACT Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first recommendations about the management of HCC. Since then, new data have emerged in the literature, prompting the governing board of SBH to sponsor a single-topic meeting in August 2018 in São Paulo. All the invited experts were asked to make a systematic review of the literature reviewing the management of HCC in subjects with cirrhosis. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration of updated recommendations. The text was subsequently submitted for suggestions and approval of all members of the Brazilian Society of Hepatology through its homepage. The present manuscript is the final version of the reviewed manuscript containing the recommendations of SBH.
- Microwave ablation: initial experience in Brazil(2020) ROVELLA, Marcello Silveira; FIORE, Lucas; ALLEGRO FILHO, Alfredo Enzo; MARTINS, Guilherme Lopes Pinheiro; MENEZES, Marcos Roberto
- Percutaneous radiofrequency ablation on a Xp11.2 Translocation Renal Cell Carcinoma: A case report(2020) KANAS, Alexandre Fligelman; ROVELLA, Marcello Silveira; MOURA, Mauricio Ruettimann Liberato de; LEITE, Katia Ramos Moreira; SROUGI, Miguel; MENEZES, Marcos Roberto deXp11.2 Translocation Renal Cell Carcinoma is a very rare subtype of renal neoplasm. The present report describes the first confirmed reported case of percutaneous ablation of this subtype of tumor. The patient presented an aggressive local recurrence 12 months after the procedure, with an infiltrative large mass occupying almost the whole kidney. The patient was submitted to radical nephrectomy. As the use of ablative methods expands, the treatment of rare renal tumor subtypes, which can present unusual clinical outcomes, may become more frequent. It is essential that these uncommon outcomes are promptly recognized, allowing early therapeutic salvage approaches.
- Management of Hepatocellular Carcinoma during the COVID-19 Pandemic - Sao Paulo Clinicas Liver Cancer Group Multidisciplinary Consensus Statement(2020) CHAGAS, Aline Lopes; FONSECA, Leonardo Gomes; COELHO, Fabricio Ferreira; SAUD, Lisa Rodrigues Cunha; ABADALA, Edson; ANDRAUS, Wellington; FIORE, Lucas; MOREIRA, Airton Mota; MENEZES, Marcos Roberto; CARNEVALE, Francisco Cesar; TANI, Claudia Megumi; ALENCAR, Regiane S. S. M.; D'ALBUQUERQUE, Luiz Augusto Carneiro; HERMAN, Paulo; CARRILHO, Flair JoseMore than 18 million people in 188 countries have been diagnosed as having coronavirus disease (COVID-19), and COVID-19 has been responsible for more than 600,000 deaths worldwide. Brazil is now the second most affected country globally. Faced with this scenario, various public health measures and changes in the daily routines of hospitals were implemented to stop the pandemic. Patients with hepatocellular carcinoma (HCC) are at an increased risk for severe COVID-19 as they present with two major diseases: cancer and concomitant chronic liver disease. The COVID-19 pandemic can significantly impact the management of HCC patients from diagnosis to treatment strategies. These patients need special attention and assistance at this time, especially since treatment for tumors cannot be delayed in most cases. The aim of this guideline was to standardize the management of HCC patients during the COVID-19 pandemic. This document was developed, on the basis of the best evidence available, by a multidisciplinary team from Instituto do Cancer do Estado de Sao Paulo (ICESP), and Instituto Central of the Hospital das Clinicas da Universidade de Sao Paulo (HC-FMUSP), which are members of the Sao Paulo Cli ' nicas Liver Cancer Group.